about
A dose-escalating phase I of imatinib mesylate with fixed dose of metronomic cyclophosphamide in targeted solid tumoursMolecular targeted therapies in advanced or metastatic chordoma patients: facts and hypotheses.Auto-immune thyroid dysfunction induced by tyrosine kinase inhibitors in a patient with recurrent chordomaCirculating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO).Best practices for the management of local-regional recurrent chordoma: a position paper by the Chordoma Global Consensus Group.Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study.Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma.Cisplatin alone or combined with gemcitabine in carcinomas of unknown primary: results of the randomised GEFCAPI 02 trial.Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study.Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy.Trabectedin in combination with doxorubicin for first-line treatment of advanced uterine or soft-tissue leiomyosarcoma (LMS-02): a non-randomised, multicentre, phase 2 trial.Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial.Efficacy of trabectedin in malignant solitary fibrous tumors: a retrospective analysis from the French Sarcoma Group.Phase II trials in patients with carcinoma of unknown primary: a pooled data analysis.Development and validation of a bedside score to predict early death in cancer of unknown primary patients.Megestrol acetate versus metronomic cyclophosphamide in patients having exhausted all effective therapies under standard careAdult desmoid tumors: biology, management and ongoing trials.Dose-levels and first signs of efficacy in contemporary oncology phase 1 clinical trialsSporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.What does a modified-Fibonacci dose-escalation actually correspond to?Predictive value of clinical judgment of tumour progression in phase II trials.Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.Adjuvant radiation therapy in metastatic lymph nodes from melanoma.Neo/adjuvant chemotherapy does not improve outcome in resected primary synovial sarcoma: a study of the French Sarcoma Group.Mechanisms of resistance to imatinib mesylate in KIT-positive metastatic uveal melanoma.Growth modulation index as metric of clinical benefit assessment among advanced soft tissue sarcoma patients receiving trabectedin as a salvage therapy.The off-label use of targeted therapies in sarcomas: the OUTC'S programStudy protocol of REGOSARC trial: activity and safety of regorafenib in advanced soft tissue sarcoma: a multinational, randomized, placebo-controlled, phase II trialGuidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†.Improvement of the initial management of sarcomas after the dissemination of evidence-based guidelines depends on the primary sarcoma location: a population-based studyGenotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.Aplidin in patients with advanced dedifferentiated liposarcomas: a French Sarcoma Group Single-Arm Phase II studySorafenib for patients with advanced angiosarcoma: a phase II Trial from the French Sarcoma Group (GSF/GETO).Head and neck soft tissue sarcomas of adult: prognostic value of surgery in multimodal therapeutic approach.PRognostic factor of Early Death In phase II Trials or the end of 'sufficient life expectancy' as an inclusion criterion? (PREDIT model).The sum of gains and losses of genes encoding the protein tyrosine kinase targets predicts response to multi-kinase inhibitor treatment: Characterization, validation, and prognostic value.Frequency of certain established risk factors in soft tissue sarcomas in adults: a prospective descriptive study of 658 casesSorafenib in metastatic uveal melanoma: efficacy, toxicity and health-related quality of life in a multicentre phase II study.Advanced chondrosarcomas: role of chemotherapy and survival.Soft tissue sarcomas or intramuscular haematomas?
P50
Q33274982-472D6B28-199C-4979-BA70-514929A5D6F6Q33275544-AEB805C5-DDD8-4592-85DB-CCC19337C820Q33276185-FFFFA89D-E2F1-437A-B374-CE1E5F109A0CQ33276211-31FE131A-55AE-4FCB-88FE-6BBBB5200E5CQ33276384-EB0D2559-E655-4270-B192-F396FF51B6C5Q33381250-DD622C19-7887-4C3D-835A-654042FF1B94Q33382803-C1BEC184-00B8-4EF3-A9F8-3918586F9625Q33399603-E319F897-6239-40BF-A099-222413384BB3Q33403930-A1605A87-BDE1-4B87-9E79-9F7429EF5DECQ33408040-3ADFD734-C78E-4E05-9E7F-D597EF8594A5Q33421348-85A5FA26-0C78-44A1-B33D-3991F6BC9EE6Q33421897-F64B5DFF-A614-4611-A7F2-349BBA37DF64Q33426789-AA260CDA-109F-47A0-82AD-DDC50B9675C8Q33441403-25D0BB36-1595-4D3A-A302-9760E9286F15Q33489537-4BE89ACD-2E9F-4994-89B4-AD880A265E03Q33794896-B811B184-E9D3-4B34-9770-F497CF7E1CD1Q33797947-B7A4635F-B73E-4EFD-B376-18178393BBFDQ33849805-0B3D5ACE-600F-40F4-94D3-395FFC9DABA7Q34039279-95BF8683-B13F-4C3A-8C0F-8CE8D3E6354AQ34348422-DC174A4B-1407-47D6-9321-50E318989F8DQ34540982-1997EC9F-3754-4D90-A792-C3ABB91E241EQ34578850-19CE43D1-FFF2-4294-A953-126C657A8380Q34585715-B7702888-3F3F-4296-AF3D-4F9BBC3A7958Q34602033-CD07EC80-A063-4080-948D-631B1BFA2741Q34660509-F7E82175-E596-4145-B8A2-AE0090BD148CQ34736667-68859816-5CE5-489F-9A16-CF72B1BAF6D7Q34897996-49BE5381-BFE9-4BDC-B33A-D725B41416BCQ35206566-83D3900F-03D4-4516-97D1-9C4804DB9AD9Q35214578-11A9CD64-3276-4669-A16B-E3EC0D6E3A33Q35583853-6F5B10DD-D87D-45C1-8072-110EB9F1C3FFQ35743233-DBA4EA69-0098-4B5A-8BE9-0B59A8703C45Q35775249-C7B7D883-3502-452E-B148-DFDA1B275FA5Q35776264-EEB06EB6-2444-4AA0-BB80-5A8F7AEA0A16Q35893485-BF213A5F-ED68-4A5C-AAAF-BF07A32A6112Q36157118-317AF6C5-E7B7-41C2-B28B-2187F9B5436BQ36413467-116B7F26-D862-4160-A9CB-0A7779CC2054Q36662584-5EAF00B9-7225-4E68-9712-CF6091E02E10Q37061324-7BE7F0B0-136C-4E89-BFFB-6732C5A1BDACQ37265042-C928BE45-7DEE-487F-8DF7-50E98D8C6AD3Q37516848-D17CCEA8-42F8-4769-B6C8-ECF9998936E5
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Nicolas Penel
@ast
Nicolas Penel
@en
Nicolas Penel
@es
Nicolas Penel
@nl
Nicolas Penel
@sl
type
label
Nicolas Penel
@ast
Nicolas Penel
@en
Nicolas Penel
@es
Nicolas Penel
@nl
Nicolas Penel
@sl
prefLabel
Nicolas Penel
@ast
Nicolas Penel
@en
Nicolas Penel
@es
Nicolas Penel
@nl
Nicolas Penel
@sl
P108
P106
P108
P1153
55816819300
P21
P31
P496
0000-0001-5243-1548